July 31, 2020

News You need - 3 Big Little Things

Announcements/News
Kate O'Reilly
&

It’s time for your monthly digital health news dose. We have looked back at three of the most noteworthy pieces of news from the last month and distilled what they mean for the industry and the key takeaways you should have on your radar. Interested in getting beyond the headlines? We’ve included three industry experts who can help you get behind these stories - just let us know if you’d like us to make the introduction!


Are we testing the right indications in the right places?

Snapshot of the Story

The Oxford University coronavirus vaccine being developed with AstraZeneca is being tested in Brazil and South Africa, as well as in the UK. Why? Because you need people with the disease to test it on. Having said that, according to a paper in Nature, of the 2,000 Covid-19 clinical trials registered around the world, more than 90 per cent are in ''wealthy'' countries, with China and India accounting for the bulk of the rest. Less affluent countries in Africa, Asia and Latin America barely get a look in. 

Why Is This Notable? 

  1. There have always been ethical questions about running trials in poorer or less developed countries because of the possible lack of people's awareness of rights, lack of regulatory rigor, and other social/ economic inequalities. So, suggesting that we ramp up testing of drugs in these nations can seem a bit controversial. 
  2. One of the things I have been concerned about during Covid-19 is that even if we do manage to develop a vaccine in record time, when will this actually reach masses in Africa and LATAM? There has been a history of medicines that are tested in rich countries taking years to reach poorer ones.
  3. Contrary to popular belief, many Asian and African countries have excellent clinical trial infrastructure and have built up expertise over the years to combat many epidemics, such as SARS and Ebola.  

Industry Implications

  1. What have we really tested, and will it work on the populations that need it most? 
  2. Testing in the right places for the right indications should be the best practice: let us not for example test malaria medication in Iceland. 
  3. On whom will the tested benefit first :Medication approval should always benefit the populations on whom they were trialled. Only seems fair, right? 
Pravin Jadhav
Pravin Jadhav
Senior Director, Innovation and Business Transformation, Corporate Projects
Otsuka Pharmaceutical Companies (U.S.)

Pravin has spearheaded a number of the R7D initiatives at his company, including optimizing trials with technology. He is very passionate about this topic.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

It isn't only just a DREAM

Snapshot of the story

Pear Therapeutics announced recruitment for a remote, 9-week insomnia treatment trial to collect real world data for a digital therapeutic (DREAM) back in February of this year. The study enrolled its first participant this week. This is an open-access, open-label, decentralized clinical trial to collect real-world evidence for PEAR-003A, a digital therapeutic delivering CBT-I. 

Why is this notable?

  1. Recruitment is virtual. 
  2. The hallowed Real World Data (RWD): Engagement, adherence, healthcare utilization, medication utilization, health economic impact, and clinical outcomes in sleep, depression and anxiety in people with chronic insomnia will be evaluated in a real-world environment.
  3. Timely alternative to dependency-inducing insomnia meds: In April, the FDA issued a new warning for several insomnia medications. Having a rigorously validated DTx as an alternative is a welcome move at this time.  

Industry Implications

  1. Quick trials for DTx: This study of 350 participants is due to finish by the end of January 2021. That's under 1 year from the kick off date. Pending meaningful results, this may imply that trials in digital health can be significantly faster when it comes to validating initial assumptions (or expectations?).
  2. Trial continuity during COVID: This is a great example of how we can continue to run trials during COVID by utilizing telehealth and remote monitoring as an alternative to in-person clinic visits. I cannot guesstimate costs, but it's safe to say it'll be cheaper! 
Megan Coder
Megan Coder
Executive Director
Digital Therapeutics Alliance

Megan founded the Digital Therapeutics Alliance and is bullish about the need for rigor in evidence generation and regulation by DTx solutions.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

CVS Pharmacy's New App for the Visually Impaired

Snapshot of the story 

CVS Pharmacy launched a new app, SpeakRx, which can read prescription labels out loud for the visually impaired. This essentially provides an audible label that reads important information including patient name, medication name, dosage and directions aloud in either English or Spanish. This new tool will help ensure that visually impaired patients are taking the correct prescriptions and as prescribed.  

Why It is Notable

Technology and Ophthalmology are striking up a friendship. Even though it is a late entrant to the digital health space, digital ophthalmology solutions are slowly but surely demonstrating potential to support patients with eye conditions  - whether it is novel POC diagnostics, or remote, mobile based visual acuity tests.  

Designing for marginalized groups: Whether it is social, economic or pathological, there seem to be certain groups that we fail to recognize to design our products and services for, and this is a step in the right direction to ensure people with visual impairment adhere to their meds.  

Industry Implications

Integration first: SpeakRx integrates with Siri or Google Assistant to read out prescription instructions.  

Slow adoption: The SpeakRx app is being rolled out in CVS outlets across the country, but it will be just the end of 2021 when the roll out phase is expected to be complete. Seems like a long time to make an app available across the country, isn't it, especially in the context of wide dissemination of mhealth during COVID? 


Kellee M. Franklin, PhD
Kellee M. Franklin, PhD
Strategic Innovation Leader
Mindful Innovation Labs

Kellee is passionate about user centric design and building products and services that truly meet the consumer/patient where they are, at a time they need it, and what they need it for.

We can provide an introduction on your behalf so that you can contact them directly with any questions/queries on this topic. Simply click on the link below to request an introduction.

Request an Introduction

Are you a HealthXL Member? See the Full Report Here

Non-HealthXL Member? You can purchase the report HERE

What’s a Rich Text element?

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.